Hypoxia can induce c‐Met expression in glioma cells and enhance SF/HGF‐induced cell migration
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The c‐Met receptor and its ligand scatter factor/hepatocyte growth factor (SF/HGF) are strongly overexpressed in malignant gliomas. Signaling through c‐Met as well as exposure to hypoxia can stimulate glioma cell migration and invasion. In several cancer cell types, hypoxia was shown to activate the c‐met promoter, which contains hypoxia inducible factor‐1 (HIF‐1) binding sites. We hypothesized that hypoxia might upregulate c‐Met also in glioma cells. Analyzing 18 different glioblastoma cell lines and 10 glioblastoma primary cultures, we found that in 50% of both the cell lines and the primary cultures c‐Met protein levels were increased following exposure to hypoxia. Upregulation of c‐met in response to hypoxia was also detected at the transcriptional level. In all primary cultures and in 16 of the 18 cell lines (89%), HIF‐1α levels were increased by hypoxia. Transfection of siRNA against HIF‐1α abgrogated the hypoxic induction of c‐Met, suggesting that c‐Met expression is upregulated by a HIF‐1α‐dependent mechanism. Hypoxia sensitized glioblastoma cell lines which showed hypoxic induction of c‐Met to the motogenic effects of SF/HGF. These findings suggest that approximately half of all human glioblastomas respond to hypoxia with an induction of c‐Met, which can enhance the stimulating effect of SF/HGF on tumor cell migration. © 2007 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1
Ceradini, D. J., Kulkarni, A. R., Callaghan, M. J., Tepper, O. M., Bastidas, N., Kleinman, M. E., Capla, J. M., Galiano, R. D., Levine, J. P., & Gurtner, G. C. (2004) · Nature Medicine · doi:10.1038/nm1075 · Cited by 2,600
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985 · cited 1×
“the latter has actually lost one of the 2 consensus elements required for the binding of p53.(37) Thus, it is more likely that other transcriptional activators must contribute to the hypoxic induction”
BackgroundKinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170
Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL
Staller, P., Sulitkova, J., Lisztwan, J., Moch, H., Oakeley, E. J., & Krek, W. (2003) · Nature · doi:10.1038/nature01874 · Cited by 870
Yuan, Y., Hilliard, G., Ferguson, T., & Millhorn, D. E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300463200 · Cited by 638 · cited 1×
“CoCl2 is a reagent that blocks the degradation of HIF-1a and is thus used to mimick hypoxic conditions.(28) Incubation with CoCl2 for 24 hr induced c-Met and HIF-1a in the same cell lines as did”
MethodIshii, N., Maier, D., Merlo, A., Tada, M., Sawamura, Y., Diserens, A., & Van Meir, E. G. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00536.x · Cited by 569 · cited 1×
“TP53 mutations were analyzed as described previously, and results were compiled from Anker et al. (1993),23 Ishii et al. (1999)24 and Kim et al. (2005).25 Immunohistochemistry for p53 was performed on paraffin sections of human glioblastomas using a mouse monoclonal antibody againt p53 (clone DO-7,…”
MethodThe hypoxic response of tumors is dependent on their microenvironment
Blouw, B., Song, H., Tihan, T., Bosze, J., Ferrara, N., Gerber, H.-P., Johnson, R. S., & Bergers, G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00194-6 · Cited by 408 · cited 1×
“showed that neoplastic astrocytes in which VEGF had been deleted grew in migrating clusters along blood vessels in the brains of athymic mice without ever forming a real tumor mass.(41) These findings suggest that when tumor neovascularization is inhibited, the lack of oxygen and nutrients can lead to a compensatory i…”
Backgroundp53 protein accumulation and gene mutations in human glioma cell lines
Anker, L., Ohgaki, H., Ludeke, B. I., Herrmann, H., Kleihues, P., & Westphal, M. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550618 · Cited by 66 · cited 1×
“TP53 mutations were analyzed as described previously, and results were compiled from Anker et al. (1993),23 Ishii et al. (1999)24 and Kim et al. (2005).25 Immunohistochemistry for p53 was performed on paraffin sections of human glioblastomas using a mouse monoclonal antibody againt p53 (clone DO-7,…”
MethodSelf-citation
Cited by
Du, R., Lu, K. V., Petritsch, C., Liu, P., Ganss, R., Passegué, E., Song, H., VandenBerg, S., Johnson, R. S., Werb, Z., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.034 · Cited by 1,130
Rosová, I., Dao, M., Capoccia, B., Link, D., & Nolta, J. A. (2008) · Stem Cells · doi:10.1634/stemcells.2007-1104 · Cited by 692
Diffuse glioma growth: a guerilla war
Claes, A., Idema, A. J., & Wesseling, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0293-7 · Cited by 636
VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
Lu, K. V., Chang, J. P., Parachoniak, C. A., Pandika, M. M., Aghi, M. K., Meyronet, D., Isachenko, N., Fouse, S. D., Phillips, J. J., Cheresh, D. A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.037 · Cited by 550
Glioblastoma: defining tumor niches
Hambardzumyan, D., & Bergers, G. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.10.009 · Cited by 522
“Hypoxia induces Met expression in GBM cells and in GBM patient samples in a HIF-dependent manner, while VEGF ablation enhances Met phosphorylation and subsequent invasion in murine and human GBM through a VEGFR2:Met complex in tumor cells [71-74].”
BackgroundImmune microenvironment of gliomas
Gieryng, A., Pszczolkowska, D., Walentynowicz, K. A., Rajan, W. D., & Kaminska, B. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.19 · Cited by 538
Cooke, V. G., LeBleu, V. S., Keskin, D., Khan, Z., O'Connell, J. T., Teng, Y., Duncan, M. B., Xie, L., Maeda, G., Vong, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.024 · Cited by 530
'Go or Grow': the key to the emergence of invasion in tumour progression?
Hatzikirou, H., Basanta, D., Simon, M., Schaller, K., & Deutsch, A. (2012) · Mathematical Medicine and Biology · doi:10.1093/imammb/dqq011 · Cited by 363
The molecular profile of microglia under the influence of glioma
Li, W., & Graeber, M. B. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos116 · Cited by 340
Neill, T., Schaefer, L., & Iozzo, R. V. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.04.029 · Cited by 304
Jensen, R. L. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9827-2 · Cited by 287
Angiogenesis and invasion in glioma
Onishi, M., Ichikawa, T., Kurozumi, K., & Date, I. (2011) · Brain Tumor Pathology · doi:10.1007/s10014-010-0007-z · Cited by 264
Jahangiri, A., De Lay, M., Miller, L. M., Carbonell, W. S., Hu, Y.-L., Lu, K., Tom, M. W., Paquette, J., Tokuyasu, T. A., Tsao, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1281 · Cited by 202
“The role for c-Met in invasiveness shown in other studies (9), and ours, could reflect 3 c-Met effects.”
BackgroundInfluentialHypoxia-regulated target genes implicated in tumor metastasis
Tsai, Y.-P., & Wu, K.-J. (2012) · Journal of Biomedical Science · doi:10.1186/1423-0127-19-102 · Cited by 190
“vasion in glioma and trophoblast cells [48,49].”
Met as a therapeutic target in HCC: Facts and hopes
Giordano, S., & Columbano, A. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.09.009 · Cited by 158
Kessler, J., Hahnel, A., Wichmann, H., Rot, S., Kappler, M., Bache, M., & Vordermark, D. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-605 · Cited by 103
“In most human cancers including malignant glioma, HIF-1a expression promotes tumor growth, angiogenesis and disease progression [ 18-20 ].”
BackgroundThe HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation
Acuña-Pilarte, K., & Koh, M. Y. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2025.06.005 · Cited by 64
Inhibition of c-Met Reduces Lymphatic Metastasis in RIP-Tag2 Transgenic Mice
Sennino, B., Ishiguro-Oonuma, T., Schriver, B. J., Christensen, J. G., & McDonald, D. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2160 · Cited by 60
Nonredundant, isoform-specific roles of HDAC1 in glioma stem cells
Lo Cascio, C., McNamara, J. B., Melendez, E. L., Lewis, E. M., Dufault, M. E., Sanai, N., Plaisier, C. L., & Mehta, S. (2021) · JCI Insight · doi:10.1172/jci.insight.149232 · Cited by 33
Metadata
- Authors
- Eckerich, C., Zapf, S., Fillbrandt, R., Loges, S., Westphal, M., & Lamszus, K.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2007-05-18
- Volume
- 121
- Issue
- 2
- Pages
- 276-283
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1987606222
- Cited by
- 133
- References
- 9
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.